It was found that the SLC16A3 gene alteration rate is highest (> 4%) in hepatobiliary cancer, endometrial cancer, pleural mesothelioma, breast cancer, and ovarian epithelial tumor (Fig. 8A), Amplification, miss mutation, and deep deletion are the main. Here, SLC16A3 is linked to breast carcinoma.